The beginning of the end: What is the future of interferon therapy for chronic hepatitis C?

Antiviral Research

Volumn 105, Issue 1, 2014, Pages 32-38

  Feld, Jordan J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Toronto Liver Centre   (Canada)

Author keywords

Cost containment; Hepatitis C; Interferon; Interferon stimulated genes (ISGs); Multidrug resistant; QUAD therapy

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ALPHA INTERFERON;

ANTIVIRAL RESISTANCE; COST BENEFIT ANALYSIS; DRUG TOLERABILITY; DRUG USE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIFE CYCLE; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; VIRUS RESISTANCE; DRUG COMBINATION; HEPATITIS C, CHRONIC; PROCEDURES; TRENDS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA;

EID: 84896132104     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.02.005     Document Type: Note

References (55)

1. N. Ank et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity J. Immunol. 180 4 2008 2474 2485
2. N. Apostolova, A. Blas-Garcia, and J.V. Esplugues Mitochondrial toxicity in HAART: an overview of in vitro evidence Curr. Pharm. Des. 17 20 2011 2130 2144
3. B.C. Bockle et al. Hepatitis C and autoimmunity: a therapeutic challenge J. Intern. Med. 271 1 2012 104 106
4. S. Bota et al. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis Clin. Drug Invest. 33 5 2013 325 331
5. L. Chen et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 128 5 2005 1437 1444 (Pubitemid 40712193)
6. L. Chen et al. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection Gastroenterology 138 3 2010 1123 1133 (e1-3)
7. S. Chevaliez, and T. Asselah Mechanisms of non-response to antiviral treatment in chronic hepatitis C Clin. Res. Hepatol. Gastroenterol. 35 Suppl. 1 2011 S31 S41
8. G.L. Davis et al. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group J. Hepatol. 11 Suppl. 1 1990 S31 S35
9. G.T. Everson Treatment of hepatitis C in the patient with decompensated cirrhosis Clin. Gastroenterol. Hepatol. 3 10 Suppl. 2 2005 S106 S112
10. J.J. Feld, and J.H. Hoofnagle Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 436 7053 2005 967 972 (Pubitemid 41191673)
11. J.J. Feld et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response Hepatology 2007
12. J.J. Feld et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study Hepatology 56 4 2012 (Suppl. Abst #81)
13. M.W. Fried et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 347 13 2002 975 982
14. E.J. Gane et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 9751 2010 1467 1475
15. E.J. Gane et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N. Engl. J. Med. 368 1 2013 34 44
16. D. Ge et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 7262 2009 399 401
17. E.J. Heathcote et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N. Engl. J. Med. 343 23 2000 1673 1680
18. C. Hezode et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N. Engl. J. Med. 360 18 2009 1839 1850
19. C. Hezode et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J. Hepatol. 59 3 2013 434 441
20. M. Honda et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2 2010 499 509
21. J.H. Hoofnagle et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report N. Engl. J. Med. 315 25 1986 1575 1578 (Pubitemid 17055392)
22. J.H. Hoofnagle, and L.B. Seeff Peginterferon and ribavirin for chronic hepatitis C N. Engl. J. Med. 355 23 2006 2444 2451 (Pubitemid 44903748)
23. I.M. Jacobson et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N. Engl. J. Med. 368 20 2013 1867 1877
24. K.V. Kowdley et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1 N. Engl. J. Med. 370 3 2014 222 232
25. P.Y. Kwo et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 9742 2010 705 716
26. M. Lagging et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection Hepatology 44 6 2006 1617 1625 (Pubitemid 44953667)
27. E. Lawitz et al. Sofosbuvir for previously untreated chronic hepatitis C infection N. Engl. J. Med. 368 20 2013 1878 1887
28. E. Lawitz et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study Hepatology 58 2013 (S1; Abst LB-4)
29. E. Lawitz et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Lancet 2013
30. B.D. Lindenbach, and C.M. Rice Unravelling hepatitis C virus replication from genome to function Nature 436 7053 2005 933 938 (Pubitemid 41191668)
31. A.S. Lok et al. Preliminary study of two antiviral agents for hepatitis C genotype 1 N. Engl. J. Med. 366 3 2012 216 224
32. S.W. Ludmerer et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay Antimicrob. Agents Chemother. 49 5 2005 2059 2069 (Pubitemid 40631625)
33. M.P. Manns et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 9286 2001 958 965 (Pubitemid 32913521)
34. I. McGilvray et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype Gastroenterology 142 5 2012 1122 1131 (e1)
35. J.G. McHutchison et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N. Engl. J. Med. 339 21 1998 1485 1492
36. NDA 205123 Simeprevir (TMC435), 2013. in Federal Drug Administration Antivrial Drugs Advisory Committee, USA. p. 1-27.
37. D. Nelson et al. High SVR Rates (SVR4) for 12-week total telaprevir combination therapy in IL28B CC treatment-naïves and prior relapsers with G1 chronic hepatitis C: CONCISE interim analysis J. Hepatol. 2013
38. J. Paeshuyse, K. Dallmeier, and J. Neyts Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action Curr. Opin. Virol. 1 6 2011 590 598
39. V. Papastergiou et al. Hepatitis C virus genotype 5: prospective evaluation of peginterferon/ribavirin treatment efficacy and predictive value of on-treatment virological responses for sustained virological response J. Clin. Gastroenterol. 48 2 2014 160 165
40. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 5 2011 1742 1751
41. J.M. Pawlotsky The results of phase III clinical trials with telaprevir and boceprevir presented at the liver meeting 2010: A new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending Gastroenterology 140 3 2011 746 754
42. L. Prokunina-Olsson et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Nat. Genet. 45 2 2013 164 171
43. F. Rahman et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C Hepatology 40 1 2004 87 97 (Pubitemid 38868927)
44. E.L. Ramos Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C J. Interferon Cytokine Res. 30 8 2010 591 595
45. A.I. Romero et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection J. Infect. Dis. 194 7 2006 895 903 (Pubitemid 44454074)
46. L. Rong et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci. Transl. Med. 2 30 2010 30ra32
47. M. Sarasin-Filipowicz et al. Interferon signaling and treatment outcome in chronic hepatitis C Proc. Natl. Acad. Sci. USA 105 19 2008 7034 7039 (Pubitemid 351754525)
48. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2 2010 447 462
49. J.W. Schoggins et al. A diverse range of gene products are effectors of the type I interferon antiviral response Nature 472 7344 2011 481 485
50. A. Soza et al. Pilot study of interferon gamma for chronic hepatitis C J. Hepatol. 43 1 2005 67 71 (Pubitemid 40805274)
51. V. Suppiah et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat. Genet. 41 10 2009 1100 1104
52. D.L. Thomas et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 7265 2009 798 801
53. P.T. Thu Thuy et al. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C J. Hepatol. 56 5 2012 1012 1018
54. S. Zeuzem et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 2013
55. S. Zeuzem et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial Hepatology 58 2013 (S1; Abst 1085)